Study Title and Description
Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial.
Key Questions Addressed
|2||Key Question 2. In adult women without preexisting breast cancer, what is the effectiveness and comparative effectiveness of medications to reduce risk for primary breast cancer on improvement in short- and long-term health outcomes, including invasive breast cancer, noninvasive breast cancer (including ductal carcinoma in situ), breast cancer mortality, all-cause mortality, and other beneficial outcomes (such as reduced fractures caused by certain medications and improved quality of life)? Key Question 2a. Does the effectiveness of risk-reducing medications vary by timing of initiation or duration of use? Key Question 2b. Does the effectiveness of risk-reducing medications persist beyond discontinuation of use?|
|3||Key Question 3. What are the harms of using medications to reduce risk for primary breast cancer? Key Question 3a. Do harms of risk-reducing medications vary by timing of initiation and/or duration of use? Key Question 3b. Do harms of risk-reducing medications persist beyond discontinuation of use?|
Primary Publication Information
|Title||Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial.|
|Author||Decensi A., Maisonneuve P., Rotmensz N., Bettega D., Costa A., Sacchini V., Salvioni A., Travaglini R., Oliviero P., D'Aiuto G., Gulisano M., Gucciardo G., del Turco MR., Pizzichetta MA., Conforti S., Bonanni B., Boyle P., Veronesi U.|
|Country||Divisions of Chemoprevention, European Institute of Oncology, Milan, Italy. firstname.lastname@example.org|
Pubmed ID: 15699284
Secondary Publication Information
There are currently no secondary publications defined for this study.
Extraction Form: Key Questions 1-4
Results & Comparisons
No Results found.